US FDA’s Top Two Vaccine Officials Announce Surprise Retirements
Executive Summary
Departures of Marion Gruber and Philip Krause may stem from White House and CDC actions related to the COVID-19 vaccines.
You may also be interested in...
COVID-19 Vaccine ‘Booster’ Or Simply A Third Dose? US FDA’s Marks Starts To Reframe The Issue
It’s a classic example of an internal dispute between an FDA review team and agency leadership playing out at an advisory committee forum, except with the highest possible stakes.
Real-World Evidence Will Take Center Stage At US FDA Advisory Committee On COVID Boosters
If regulators agree with Pfizer’s conclusions – and briefing documents suggest that’s a big if – about real-world studies showing Comirnaty’s effectiveness waning over time, thereby justifying the need for a booster dose, it could be part of a historical moment for FDA’s use of RWE.
Biden’s Trump Moment? COVID Booster Messaging Complicated After Top FDA Scientists Raise Doubts
As questions of political interference continue to swirl around the issue of whether additional vaccine shots will be needed, the Biden administration is facing communication challenges commonly seen with his predecessor, Donald Trump.